Extended Data Fig. 4. Time on targeted therapy before the first dose of IT nivolumab in BRAF mutant patients who were treated with concurrent BRAF/MEK inhibitors (n = 11).

Patients were treated with 20 mg (n = 7) and 50 mg (n = 4) of IT nivolumab. Only 4 patients remain alive at data lock.